Bloomberg News

4SC Says Anti-Cancer Compound Resminostat Gets Positive Opinion

October 13, 2011

Oct. 13 (Bloomberg) -- 4SC AG said its anti-cancer compound Resminostat was designated by the European Medicines Agency as orphan medicinal product for the treatment of Hodgkin’s Lymphoma.

Link to Statement:{NSN LSZONF3PR6RK <GO>}

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net


Steve Ballmer, Power Forward
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus